Cyclobenzaprine overdose

# Overdose topics
Anxiety disorders
Manifestations
Management
- General management
- Gastrointestinal Decontamination
- Cardiovascular
- CNS
- Psychiatric Fallow-up
- Pediatric Management

## General
Although rare, deaths may occur from overdpsage with Cyclobenzaprine HCL. Multiple
drug ingestion (including alcohol) is common in deliberate Cyclobenzaprine overdose.
As management of overdose is complex and changing, it is recommended that
the physician contacta poison control center for,current information on
treatment. Signs and symptoms of toxicity may develop rapidly after cyclobenzaprine
-verdose; therefore, hospital monitoring is required as soon as possible. The acute oral
LD50 of Cyclobenzaprine HCI is approximately 338 and 425 mg/kg in mice and rats,
respectively. Return to top

## Manifestations
The most common effects associated with Cyclobenzaprine overdose are drowsiness and tachycardia. Less frequent manifestations include tremor, agitation, coma, ataxia, hypertension, slurred speech, confusion, dizziness, nausea, vomiting, and hallucinations. Rare but potentially critical manifestations of overdose are cardiac arrest, chest pain, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particulary in QRS axis or width, are clinically significant indicators of Cyclobenzaprine toxicity. Return to top

## General management
In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patients airway, establish an intravenous line and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug.Return to top

## Gastrointestinal Decontamination
All patients suspected of an overdose with Cyclobenzaprine HCl tablets should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and emesis is contraindicated. Return to top

## Cardiovascular
A maximal limb-lead QRS duration of >0.10 seconds may be the best indication of the severity of the overdose. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be instituted for patients with dysrhythmias and/or QRS widening. A pH >7.60 or a pCO2<20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide). Return to top

## CNS
In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g. phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center. Return to top

## Psychiatric Fallow-up
Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery phase. Psychiatric referral may be appropriate. Return to top

## Pediatric Management
The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment. Return to top
Adapted from the FDA Package Insert.